Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (June 2020)
35 slides from Sutro Biopharma's investor presentation, Jun 15, 2020
Slide 1: Company Overview June 2020
Company Overview June 2020 NASDAQ: STRO Bill Newell, CEO Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: The Sutro Vision: Changing the Future of Oncology
The Sutro Vision Changing the Future of Oncology PLATFORM FINANCIAL RESOURCES PARTNERS PEOPLE PRODUCTS 3 Clinical Programs in 2018-19 2 more projected in 2020-21 Team With Proven Track Record of Executing Cash, cash equivalents, and marketable securities balance of $129.6M as of March 31, 2020 Plus
Slide 4: Sutro Clinical Pipeline
Sutro Clinical Pipeline Owned and Partnered Programs Program Discovery Preclinical Phase 1 Phase 2/3 Milestone Commercial Rights Ovarian and Endometrial Cancer FolRα - Targeting ADC STRO-002 CD74 - Targeting ADC STRO-001 Multiple Oncology Programs including iADCs Cytokine Derivatives Commence Dose E
Slide 5: STRO-002 Emerging Safety Profile and Evidence of Anti-tumor Activity
STRO-002 Emerging Safety Profile, Evidence of Anti-tumor Activity and Clinical Benefit are Encouraging – AACR April 27, 2020 62% (13/21) Patients at 2.9 mg/kg or higher with post baseline assessments have had a ≥ 50% reduction in CA-125 levels or normalization of CA-125 100% (12/12) All evaluable pa
Slide 6: Interim Analysis Shows Promising RECIST Response and Stable Disease
Interim Analysis Shows Promising RECIST Response and Stable Disease In an Unselected, Resistant and Refractory Patient Population 2.9 mg/kg 4.3 mg/kg 6.0 mg/kg 5.2 mg/kg 5.6 mg/kg Ongoing Best % change in sum of target lesions from baseline N=20 evaluable patients treated at ≥ 2.9 mg/kg +30 +19 +19
Slide 7: CD74-targeting ADC (STRO-001) Phase 1 initial safety and efficacy data
CD74-targeting ADC (STRO-001) Phase 1 initial safety and efficacy data in multiple myeloma (MM) and NHL 33 patients enrolled, heavily pretreated (Jan 2020) MTD not yet determined Dose escalation continuing above 0.91 mg/kg No ocular toxicity observed & generally well tolerated 1 CR and 1 PR observed
Slide 8: Sutro's Anticipated Upcoming Milestones: 2020
Sutro’s Anticipated Upcoming Milestones: 2020 Milestones for Sutro Proprietary Programs Anticipated Timing FolRα-targeting ADC (STRO-002) - Phase 1 Additional dose escalation clinical data Updated dose escalation clinical data Commence dose expansion 2Q 2020 2H 2020 2H 2020 CD74-targeting ADC (STRO-
Slide 9: Delivering On Our XpressCF Collaborations
Delivering On Our XpressCF+TM Collaborations ~ $370 Million in Payments Received through 2019 from Collaborators Cytokine Derivatives: 1st program lead optimization achieved in 18 months More robust design approach than Synthorx approach Approaching $100M total funding received to date Up to $1.6B p
Slide 10: Sutro's Approach Delivering Potentially Best-in-Class ADCs and Cytokine Conjugates
10 Sutro’s Approach Delivering Potentially Best-in-Class ADCs and Cytokine Conjugates Widening the Therapeutic Index is Key to Achieving Best-in-Class Performance The Sutro Advantage Rapid iterative design to identify best-in-class product candidates Selection of specific sites for conjugation for o
Slide 11: FolRα-Targeting ADC STRO-002
FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002
Slide 12: Phase 1 Clinical Trial Design
Phase 1 Clinical Trial Design Fast Track FDA Registration Pathway Possible Based on Recent Precedent Key Objectives Part 1: Safety, MTD, RP2D, PK, ADA, preliminary efficacy Part 2: Response rates, duration of response, PFS, safety, PK *DOSE LEVEL n Part 2 — Dose Expansion (2 Cohorts) STRO-002 Dose L
Slide 13: Patient Demographics and Disease Characteristics
Patient Demographics and Disease Characteristics Reported April 27, 2020 (Data as of April 20, 2020) Characteristic Total N = 30 (%) Age, median (range), years 60.5 (47-76) Tumor type EOC 25 (83) Fallopian tube 3 (10) Primary peritoneal 2 (7) ECOG PS 0 17 (57) 1 13 (43) Median time from diagnosis (r
Slide 14: 62% of Patients Had ≥50% Reduction or Normalization of CA-125
62% (13/21) of Patients Treated at ≥ 2.9 mg/kg with Post- Baseline Assessments Had ≥ 50% Reduction or Normalization of CA-125 50% reduction X axis- post C1D1 assessments Y axis- change from C1D1 CA-125 Data as of April 20, 2020 CA-125 Responses 6 confirmed CA-125 responses 1 sustained CA-125 normali
Slide 15: 35% of Evaluable Patients Remained on Study > 24 Weeks
35% (7/20) Patients Evaluable for Progression at ≥ 2.9 mg/kg Remained on Study > 24 weeks 2.9 mg/kg 4.3 mg/kg 6.0 mg/kg Duration calculated as time to PD from 1st dose or according to doses received (2 doses = 3 weeks, 3 doses= 6 weeks, etc.) 5.2 mg/kg 5.6 mg/kg 6.4 mg/kg On study PD leading to disc
Slide 16: 75% of Patients Had Stable Disease or Partial Response
75% (15/20*) of Patients Treated at ≥ 2.9 mg/kg Have Initial Post-Baseline Scans That Showed Stable Disease or Partial Response 2.9 mg/kg 4.3 mg/kg 6.0 mg/kg 5.2 mg/kg 5.6 mg/kg 6.4 mg/kg On study Confirmed PR Unconfirmed SD Confirmed SD Unconfirmed PR PD (RECIST or UCP) Data as of April 20, 2020 On
Slide 17: All Patients with CA-125 Response Remain on Study Treatment
All Patients with CA-125 ≥ 50% Reduction or Normalization Remain on Study Treatment and 100% (12/12) Achieved Tumor Control 2.9 mg/kg 4.3 mg/kg 6.0 mg/kg 5.2 mg/kg 5.6 mg/kg 6.4 mg/kg On study Confirmed PR Unconfirmed SD Confirmed SD Unconfirmed PR PD (RECIST or UCP) Data as of April 20, 2020 Confir
Slide 18: Promising Interim Analysis Demonstrates RECIST Response and Stable Disease
2.9 mg/kg 4.3 mg/kg 6.0 mg/kg 5.2 mg/kg 5.6 mg/kg Ongoing Best % change in sum of target lesions from baseline N=20 evaluable patients treated at ≥ 2.9 mg/kg +30 +19 +19 +7 +1 0 0 0 -2 -3 -5 -5 -7 -9 -18 -19 -21 -22 -22 -88 Only 1 post baseline scan On study > 24 wks Data as of April 20, 2020 1 2 3
Slide 19: Treatment Emergent AEs in ≥20% of Patients
Treatment Emergent AEs in ≥ 20% of Patients (without causality attribution) Data as of April 20, 2020 Treatment Emergent Adverse Events (TEAE) TEAE >20% Grade 1 Grade 2 Grade 3 Grade 4* N= 29 (%) Fatigue 7 (24) 10 (35) 2 (7) 19 (66) Nausea 13 (45) 4 (14) 17 (59) Neutropenia/ Neutrophil count decreas
Slide 20: Summary - Well Tolerated, Encouraging Clinical Benefit
Summary - Well Tolerated, Encouraging Clinical Benefit Expansion Cohorts Planned for 2H 2020 STRO-002 was generally well tolerated and mostly associated with mild events 5/30= 17% have not had post-treatment scan for initial RECIST assessment 89% of all AEs reported are grade 1 or 2 Prophylactic cor
Slide 21: FolRα Studies with Similar Heavily Pre-Treated Ovarian Cancer Populations
FolRα Studies with Similar Heavily Pre-Treated, Unselected Ovarian Cancer Patient Populations in Phase 1 Dose Escalation STRO-002 (n = 30) Mirvetuximab (n = 44)** Ovarian (n = 23) Endometrial CA (n = 11) XMT-1536 (n=48)*** Ovarian (n=37) NSCLC (n=11) Trial status/ presentation 4/20/20 update - Ongoi
Slide 22: Anti-Tumor Activity of STRO-002 is Encouraging
Anti-Tumor Activity of STRO-002 is Encouraging STRO-002 (n = 25) ≥ 2.9 mg/kg Mirvetuximab (n = 23)* 39/44 (89)% ≥ 3.3 mg/kg43.3 mg/ XMT-1536 (n=43)** Ovarian (34) and NSCLC (9) ≥ 20 mg/m2 Efficacy Analysis Interim - Ongoing Final Near Final, Data analysis 2/3/20 CA-125 responses 6 confirmed 6 unconf
Slide 23: 35% of Patients at ≥2.9 mg/kg Remain on Study >24 Weeks
Anti-Tumor Activity of STRO-002 is Encouraging 35% of Patients at ≥ 2.9 mg/kg Remain on Study >24 weeks STRO-002 (n = 25) ≥ 2.9/mg Mirvetuximab (n = 23)* XMT-1536 (n=43)** Ovarian (34) and NSCLC (9) ≥ 20 mg/m2 Remaining on study treatment 68% of patients None 12% of patients (5/43) On study ≥ 24 wee
Slide 24: CD74-Targeting ADC: Phase 1 Potential First and Best-in-Class ADC
CD74-Targeting ADC: Phase 1 Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001
Slide 25: Phase 1 Clinical Trial Design
Phase 1 Clinical Trial Design Clinical data will drive expansion decision making in 2020 Part 2 — Dose Expansion (4 Potential Cohorts) Part 1 — Dose Escalation (2 Cohorts) Dose Level 1 Dose Level 2 DOSE LEVEL n Advanced and/or Refractory Multiple Myeloma Advanced and/or Refractory NHL Multiple Myelo
Slide 26: Patient Demographics First Patients
Patient Demographics First 25 Patients – ASH Abstract November 2019 Characteristics Cohort A (MM) N =14 Cohort B (NHL) N=11 Total N=25 Age, median (range), years 64.5 (42-80) 64 (21-82) 64 (21-82) Median time from diagnosis in years (range) Disease Subtype, N (%) Multiple myeloma 14 (100) N/A 14 (56
Slide 27: Generally Well Tolerated with Early Signs of Anti-Tumor Activity
Generally Well Tolerated with Early Signs of Anti-Tumor Activity Presented at EHA June 2019 and Updated in ASH Abstract November 2019 STRO 001 STRO-001 was generally well tolerated, most AEs were Grade 1 & 2 No ocular toxicity signals have been observed Preliminary anti-tumor activity: DLBCL: 1CR &
Slide 28: CR and PR Observed in Two of Five Patients with DLBCL
CD74 - targeting ADC (STRO-001) 1 CR and 1 PR have been observed in two of five patients with DLBCL. Presented at EHA June 2019. 0.05 mg/kg 0.075 mg/kg 0.15 mg/kg 0.29 mg/kg 0.43 mg/kg 0.65 mg/kg 0.91 mg/kg Still on study treatment DLT Disease progression Complete response Partial response Cohort B-
Slide 29: Stable Disease in One Patient with MM
CD74 – targeting ADC (STRO-001) Stable disease in one patient with MM. Data as of July 2019 0.05 mg/kg 0.075 mg/kg 0.15 mg/kg 0.29 mg/kg 0.43 mg/kg 0.65 mg/kg 0.91 mg/kg Still on study treatment DLT Disease progression Complete response Partial response Cohort A-MM Duration on Treatment Weeks from F
Slide 30: CC-99712 (BCMA ADC) Phase 1 Study
CC–99712 (BCMA ADC) Phase 1 Study Enrolling Patients with Relapsed Refractory Multiple Myeloma CC 99712 BCMA – targeting ADC Potentially Available in Community Oncology Centers CC-99712 was discovered and developed using Sutro’s XpressCF® Source: Bristol-Myers Squibb ASH 2019. BCMA ADC CC-99712 BCMA
Slide 31: GSK2857916 (BCMA ADC) DREAMM-2 Pivotal Study
GSK2857916 (BCMA ADC) – DREAMM-2 Pivotal Study Modest Efficacy & Ocular Toxicities Suggest Narrow Therapeutic Window Ocular Toxicities Grade 3/4 keratopathy occurred in 27% of patients Keratopathy resulted in dose reductions in 23% of patients and treatment delays in 47% of patients (starting at wee
Slide 32: Next Generation Tumor Targeting Immunostimulatory ADC
Sutro’s Next Generation Tumor Targeting Immunostimulatory ADC Breakthrough technology for dual conjugated immunostimulatory antibody drug conjugate Designed and enabled using Sutro’s XpressCF+TM platform Enables simultaneous and precise tumor targeting of a cytotoxin and a novel toll-like receptor (
Slide 33: Enhanced Immune Cell Activation and Anti-Tumor Immunity
Provides Enhanced Immune Cell Activation and Anti-Tumor Immunity Early activation of DCs Spleen of treated mice Control iADC (+ TLR) ADC ISAC (TLR alone) iADC single dose causes some complete response MC38-FolR mouse model iADC treated mice resistant to future re-challenge Simultaneous delivery of c
Slide 34: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD Chief Scientific Officer Arturo Molina, MD, MS, FACP Chief Medical Officer Ed Albini Chief Financial Officer Shabbir Anik, PhD Chief Technical Operations Officer Linda Fitzp
Slide 35: Company Overview June 2020
Company Overview June 2020 NASDAQ: STRO Bill Newell, CEO